The 2nd Annual Next Generation Cancer Vaccine Development Summit returns as the only industry-dedicated meeting bringing you the most up-to-date clinical and commercial developments utilizing next-generation vaccines for solid tumours and other cancers.
Why have we failed in the past and how can we succeed in the future? By deciphering the challenges of antigen selection, point mutations, delivery, and resistance mechanisms, the 2nd Next Generation Cancer Vaccine Development Summit will focus on overcoming the translational and clinical challenges of therapeutic and prophylactic vaccines for oncology indications.
Gain access to fresh studies and discussions covering 鈥楶ersonalized vs Off-the-Shelf鈥�, shared neoantigens, immuno-stimulating adjuvants, understanding the tumour microenvironment, and insights into cancer vaccine candidates currently under clinical assessment.
Why have we failed in the past and how can we succeed in the future? By deciphering the challenges of antigen selection, point mutations, delivery, and resistance mechanisms, the 2nd Next Generation Cancer Vaccine Development Summit will focus on overcoming the translational and clinical challenges of therapeutic and prophylactic vaccines for oncology indications.
Gain access to fresh studies and discussions covering 鈥楶ersonalized vs Off-the-Shelf鈥�, shared neoantigens, immuno-stimulating adjuvants, understanding the tumour microenvironment, and insights into cancer vaccine candidates currently under clinical assessment.
